Jonathan S. Zager, MD

Articles by Jonathan S. Zager, MD

Jonathan S. Zager, MD, on Results of Phase 3 FOCUS Trial Examining Percutaneous Hepatic Perfusion in Ocular Melanoma With Hepatic Metastases

September 27th 2022

Jonathan S. Zager, MD, discussed the use of percutaneous hepatic perfusion vs best alternative care for patients with hepatic-dominant ocular melanoma analyzed in the phase 3 FOCUS trial.

POINT: Surgical Management of Lymph Node Basin in Sentinel Lymph Node–Positive Melanoma

ByAmod A. Sarnaik, MD,Jonathan S. Zager, MD,Vernon K. Sondak, MD

October 15th 2016

CLND as standard of care for patients with SLN-positive metastatic melanoma is supported by a wealth of compelling prospective data.

Jonathan S. Zager, MD

Articles by Jonathan S. Zager, MD

Jonathan S. Zager, MD, on Results of Phase 3 FOCUS Trial Examining Percutaneous Hepatic Perfusion in Ocular Melanoma With Hepatic Metastases

POINT: Surgical Management of Lymph Node Basin in Sentinel Lymph Node–Positive Melanoma

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC

Achieving a “Functional Cure” With Multiple Myeloma Therapy